Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Pancreatic Neoplasms

• A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
• Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
• Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
• Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
• A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemo
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
• Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
• A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
• Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
• Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
• Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
• A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
• A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
• Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.
• Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
• Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
• Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
• Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
• The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
• A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
• CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
• Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
• NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
• AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
• Olaparib in PALB2 Advanced Pancreatic Cancer
• The Seven Trial: Exploiting the Unfolded Protein Response
• Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
• Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
• Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC
• TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
• Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
• Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
• Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
• ZN-c3 + Gemcitabine in Pancreatic Cancer
• Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
• A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
• Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
• Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
• HTL0039732 in Participants With Advanced Solid Tumours
• Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
• Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
• Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
• A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
• Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
• Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis
• Canagliflozin With Gemcitabine in Pancreatic Carcinoma
• Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma
• GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
• A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
• Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients With Non-resectable Pancreatic Cancer
• Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
• Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
• A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
• IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
• Proglumide With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
• Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer
• The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
• The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
• The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
• Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
• DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
• SBRT Plus vNKT for Pancreatic Cancer
• Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
• Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
• Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
• HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
• Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
• EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
• Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer
• Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
• Clinical Trial of CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
• Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
• Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
• Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
• Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations
• A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
• Clinical Study of Tumor Treating Fields Combined With Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
• A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3
• Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
• Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
• Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
• Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
• Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
• Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
• Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
• AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer
• Study of BMF-219 in Adult Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer.
• Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
• Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic Ultrasound
• A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer
• Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo
• Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
• U87 CART in Treatment of Advanced Pancreatic Cancer
• A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
• A Randomized Controlled Study of Suizenji in Patients With Unresectable Pancreatic Cancer
• Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)
• A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
• Safety, PK and Efficacy of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
• A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
• A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
• Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
• A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
• Neoadjuvant FOLFIRINOX in Resectable Pancreatic Cancer
• Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
• An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma
• PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
• A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract or Pancreas
• A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
• A Phase 2, Randomized, Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Advanced Metastatic Pancreatic Cancer: PAAG.
• A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
• Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
• Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
• Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
• A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of MB1707 in Patients With Advanced Cancer
• Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
• Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
• The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
• Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
• Switch Maintenance in Pancreatic
• FOLFIRINOX + NIS793 in Pancreatic Cancer
• Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
• Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer
• A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
• Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases
• Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma
• Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
• Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
• Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
• AMP946 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
• A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.
• A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
• An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
• Phase 1b/2 Study of HCW9218 for Advanced Pancreatic Cancer
• Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
• Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
• Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
• Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
• A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
• Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
• Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
• Pre- vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
• Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
• Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
• DDP ip Combined With AG in PDAC With Peritoneal Metastasis
• Palliadelic Treatment to Reduce Psychological Distress in Persons With Inoperable Pancreatobiliary Cancer
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
• Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
• Adavosertib and Gemcitabine in Advanced Pancreatic
• A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
• Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
• SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
• Conformal Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer That Has Spread to the Liver
• Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
• Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
• The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
• PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
• The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
• A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
• Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
• First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
• First in Human Pancreatic Cancer Trial
• A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
• CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab
• Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
• MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
• Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
• Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
• Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
• ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
• Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
• Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
• Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
• Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
• Investigator-initiated Clinical Trial of MIKE-1
• A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
• Cabozantinib and Pembrolizumab in Metastatic Pancreas
• Peri-operative SLOG for Localized Pancreatic Cancer
• Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
• Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
• Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
• Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
• A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
• Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
• Mutant Kirsten Rat Sarcoma (KRAS) -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
• Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Pancreatic Cancer
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
• Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
• Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
• A Phase I Trial of ProAgio, an Anti- Alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
• High Dose Omeprazole in Patients With Pancreatic Cancer
• A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
• Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
• Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
• Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
• Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
• Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer
• Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
• Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
• Study of a New Technique for Imaging Pancreatic Cancer
• Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
• Cholesterol Disruption in Combination With FOLFIRINOX in Patients With Metastatic Pancreatic Adenocarcinoma
• A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial
• Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
• Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
• PanDox: Targeted Doxorubicin in Pancreatic Tumours
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
• Anamorelin Study for Advanced Pancreatic Cancer
• Electroporation Potentiated Immunotherapy in Cancer
• Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
• Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
• Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
• Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
• Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
• EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
• Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
• Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With U
• Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
• Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
• A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
• Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab
• Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
• Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
• Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
• Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With BI 754091 to Patients With Advanced Solid Tumors Having the B7-H6 Marker
• An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy
• The Transformation of Locally Advanced Pancreatic Cancer.
• Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer
• Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy
• TH1902 in Patients With Advanced Solid Tumors
• Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
• Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141
• A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastati
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
• Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
• LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors
• First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
• SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
• APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
• Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
• Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
• A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
• AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
• Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
• Paricalcitol Trial
• Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
• PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
• Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
• Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
• MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients
• Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
• Carbon Ion RT for Locally Advanced Pancreatic Cancer
• Saltikva for Metastatic Pancreatic Cancer
• The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
• Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
• A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
• Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
• NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
• Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
• Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
• Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
• PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
• Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
• Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
• Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
• Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
• New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
• A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
• Pancreatic Adenocarcinoma Signature Stratification for Treatment
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
• Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
• Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
• A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer
• A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
• Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes
• The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
• Niraparib + Dostarlimab + RT in Pancreatic Cancer
• FAZA PET/MRI Pancreas
• Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
• Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
• LY3214996 +/- HCQ in Pancreatic Cancer
• A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
• Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
• NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
• Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
• Effect of Thrombin-containing Collagen-based Hemostatic Matrix
• Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
• RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
• Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
• Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
• Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
• Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions
• A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
• Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
• Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer
• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
• Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
• Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
• Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
• Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
• Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer
• Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
• Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
• A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
• A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
• Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
• Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients
• Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
• L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
• A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
• Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
• The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
• SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
• Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
• Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
• Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
• Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
• An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
• A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
• FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
• A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
• Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
• Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
• Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
• A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
• Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
• Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
• INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
• Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
• Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
• Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
• 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
• MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
• mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
• A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
• A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
• Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
• Lidocaine Infusion in Pancreatic Cancer
• Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
• Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
• High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
• Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
• Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
• A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
• Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
• An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
• Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer
• Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
• Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
• Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
• Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
• Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer
• Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
• Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
• Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer
• A Safety Study of SGN-CD47M in Patients With Solid Tumors
• Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
• Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
• Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
• Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
• Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
• High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
• A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
• Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
• Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
• Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
• Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
• Study of Proton Therapy in Adjuvant Pancreatic Cancer
• Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
• Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
• Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
• Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
• A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
• Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
• Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
• CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
• Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
• Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery
• Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
• A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )
• Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
• Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
• A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
• A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
• Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
• Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer
• Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
• High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
• 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
• SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
• Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
• Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
• Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1
• Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
• Masitinib Plus Gemcitabine in Pancreatic Cancer
• A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors
• Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
• Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
• Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
• A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
• Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
• SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients
• Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
• Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
• CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
• Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
• High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
• Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
• First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
• Phase II Trial of AZD6738 Alone and in Combination With Olaparib
• First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
• 9-ING-41 in Patients With Advanced Cancers
• Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabi
• Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
• Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
• A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
• Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer
• Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
• BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
• Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
• Acelarin First Line Randomised Pancreatic Study
• iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
• A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• Niraparib in Patients With Pancreatic Cancer
• Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
• Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
• Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
• A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies
• DC Vaccine in Pancreatic Cancer
• QUILT-3.080: NANT Pancreatic Cancer Vaccine
• Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer
• Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer
• Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
• Bethanechol Prior to Pancreatic Surgery
• Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
• QUILT-3.088: NANT Pancreatic Cancer Vaccine
• Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
• PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
• A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients
• Biological Effect of Warfarin on Pancreatic Cancer
• Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
• A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
• A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer
• Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
• Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
• A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer
• CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
• A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer
• Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
• Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer
• Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
• Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
• In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer
• First-line Therapy in Metastatic PDAC
• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
• Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
• A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer
• Study of NEO-201 in Solid Tumors Expansion Cohorts
• High-dose Vitamin D3 in Pancreas Cancer
• Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
• 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
• A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
• CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
• Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
• M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
• Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery
• Divestment for Artery-involved Pancreatic Cancer
• SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
• Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
• Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
• A Study of ABTL0812 in Pancreatic Cancer
• Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
• Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
• A Study of ASN007 in Patients With Advanced Solid Tumors
• Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
• Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
• The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
• Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
• The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
• Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy
• Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
• QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
• IMX-110 in Patients With Advanced Solid Tumors
• Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
• CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
• Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer
• TAS102 in Combination With NAL-IRI in Advanced GI Cancers
• Two Chemotherapy Regimens Plus or Minus Bevacizumab
• Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
• Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
• Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
• A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
• A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy
• A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
• QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
• Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
• Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
• S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer
• Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
• Stromal TARgeting for PAncreatic Cancer (STAR_PAC)
• PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
• Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
• A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
• IACS-010759 in Advanced Cancers
• Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
• To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
• Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
• The Effect of Application of TachoSil® in Pancreatoduodenectomy
• BATs Treatment for Pancreatic Cancer, Phase Ib/II
• Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
• Azacitidine and Pembrolizumab in Pancreatic Cancer
• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
• Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
• Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
• Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.
• A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
• Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
• Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery
• Bioinformation Therapy for Pancreatic Cancer
• To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
• Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia
• AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
• An Open Label Study to Evaluate G17DT Compared to Gemcitabine
• Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
• Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
• Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
• RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
• Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
• A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
• Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
• A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer
• First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
• Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers
• GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
• Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
• High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
• Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
• A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
• Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
• QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
• A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
• EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
• Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
• A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer
• Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
• Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
• Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
• A CR-UK Phase I Trial of LY3143921
• Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
• Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
• A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
• TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
• Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer
• Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
• A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
• Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
• FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
• Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
• A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
• Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
• Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
• High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer
• Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
• A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
• PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
• Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
• Clinical Application of IRE Combined With Chemotherapy in the Treatment of Pancreatic Cancer
• IORT Versus CCRT for Pancreatic Cancer
• Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
• Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
• Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
• A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
• A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
• Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
• Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
• Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
• Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
• Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
• TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
• Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
• Nordic Pancreatic Cancer Trial (NorPACT) - 1
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
• PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
• Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
• A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
• Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
• Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
• Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
• Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
• Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
• A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
• Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
• Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
• A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer
• Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients
• A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
• Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer
• HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
• p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
• Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
• FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
• Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)
• Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients
• Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
• A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
• Pasireotide Treatment for Neuroendocrine Tumor
• Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
• Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
• HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
• Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
• Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients
• Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
• Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes
• Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
• Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma
• Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
• Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
• IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer
• A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
• The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery
• Apatinib as Second-line Treatment of Advanced Pancreatic Cancer
• Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
• Ultrasound Monitoring of Abdominal Soft Tissue
• K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability
• Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
• Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
• A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer
• Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
• A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
• Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
• LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
• Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
• Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
• A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
• Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
• Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
• Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
• EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer
• Epidural Analgesia Use in Pancreatic Resections
• Olaparib in Treating Patients With Stage IV Pancreatic Cancer
• Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
• Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
• Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
• T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
• Study of SBP-101 in Pancreatic Cancer
• Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer
• Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
• Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
• BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
• Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
• Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer
• Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis
• A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
• Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy
• Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
• [68 Ga]-DOTANOC PET/CT in GEP-NETs
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
• Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
• Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
• Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
• Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
• Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
• Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
• FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
• Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
• TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
• Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
• First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
• S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
• Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
• Treatment of Pancreatic Cancer With Abraxane
• Exceptional Responders With Pancreatic Cancer to Chemotherapy
• Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
• Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
• A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
• Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
• ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
• Efficacy and Safety of PARPi to Treat Pancreatic Cancer
• Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
• Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
• A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
• Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
• A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
• Incretin-based Drugs and Pancreatic Cancer
• Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)
• Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
• Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
• Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
• Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
• Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery
• Survivorship Promotion In Reducing IGF-1 Trial
• A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
• Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
• Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
• A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
• Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer
• Octreotide LAR as Maintenance Treatment for Patients With NEC
• Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
• Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
• A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
• A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
• Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
• Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma
• Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
• Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
• Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
• The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
• OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma
• ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
• Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
• Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer
• Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
• First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
• FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer
• Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
• Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
• Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
• Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
• Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
• CTC Pancreatic Adenocarcinoma
• Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
• Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
• Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
• Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
• Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
• Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
• Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
• Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
• Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
• Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
• Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
• Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
• Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
• Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
• Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
• A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
• Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
• Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
• Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
• Study of Gemcitabine and Abraxane for Pancreas Cancer
• Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
• Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
• A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
• Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
• A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
• Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
• Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
• Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer
• A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
• Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
• A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
• Cancer Associated Thrombosis and Isoquercetin (CATIQ)
• Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
• Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
• Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
• Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
• 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
• Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
• BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
• Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
• A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
• Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
• αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
• Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
• A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
• Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
• Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
• (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
• S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer
• Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
• Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
• Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer
• A Study of Ruxolitinib in Pancreatic Cancer Patients
• Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
• Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
• Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel
• Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
• Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
• An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
• Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
• A Study of Regorafenib in Advanced Pancreatic Cancer Patients
• BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
• Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
• Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
• DCE MRI in Patients With Pancreatic Cancer
• Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
• Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
• Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
• Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
• Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
• A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
• Effects of Dexmedetomidine During IRE Procedures for Solid Tumours
• Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
• Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
• A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
• Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
• A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
• mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
• Etomidate vs. Midazolam for Sedation During ERCP
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
• Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
• Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
• BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
• A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
• A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
• Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
• Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
• A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
• Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
• The Cancer of the Pancreas Screening-5 CAPS5)Study
• Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study
• In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study
• A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
• Borderline Pancreas Study: FOLFIRINOX +SBRT
• The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome
• Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
• Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer
• Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.
• Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
• Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
• Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
• Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
• Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
• Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer
• Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy
• Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
• Analgesia and Pancreatic Cancer Surgery
• Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
• Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
• Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.
• High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
• Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
• A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
• Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer
• Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
• Neoadjuvant Treatment in Resectable Pancreatic Cancer
• Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
• FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
• Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
• Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
• Molecularly Tailored Therapy for Pancreas Cancer
• Maintenance Dovitinib for Colorectal and Pancreas Cancer
• A Phase II Study of Locally Advanced Pancreatic Cancer
• Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
• Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
• Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
• Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)
• Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
• Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
• 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
• CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
• A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
• Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
• CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
• QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
• EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer
• A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
• 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
• Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
• Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
• ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery
• An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
• Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
• Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
• Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery
• SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
• QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
• Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
• Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
• Adjuvant Effect of Chloroquine on Gemcitabine
• Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
• Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
• Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study
• Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
• Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
• Safety and Feasibility Study of Enhanced Recovery in Pancreaticoduodenectomy
• GTX-RT in Borderline Resectable Pancreatic Cancer
• TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
• BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
• Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
• A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
• Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer
• Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
• Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
• Role of Perfusion CT in Pancreatic Cancer
• A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
• Minocycline Study in Pancreatic Cancer Patients
• S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
• Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
• FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
• Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
• Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
• A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
• Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
• A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
• A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
• A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
• Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
• Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
• Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
• Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
• Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
• A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
• Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
• M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
• The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
• Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
• OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
• Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
• Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
• EGF Ointment for Erlotinib Skin Lesion
• FOLFIRINOX + RT for Pancreatic Cancer
• Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
• A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
• BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
• Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
• Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
• Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer
• Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
• Second Line Chemotherapy for Advanced Pancreatic Cancer
• Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
• Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
• Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
• Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions
• Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
• Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
• Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
• Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer
• Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
• NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer
• A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
• Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
• A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
• A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
• A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
• A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
• Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer
• Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
• Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
• Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
• ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
• Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
• ABC294640 in Treating Patients With Advanced Solid Tumors
• Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
• LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
• Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
• Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
• A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
• Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
• A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
• Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane
• Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
• Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
• Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
• Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets
• Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
• Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
• Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects
• Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
• Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
• TKM 080301 for Primary or Secondary Liver Cancer
• Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
• Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer
• Study of Ruxolitinib in Pancreatic Cancer Patients
• Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
• Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
• Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
• FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
• Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
• A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma
• Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
• Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer
• Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer
• Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
• Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
• HYPAZ: Hypertension Induced by Pazopanib
• CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
• SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
• FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
• A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
• Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity
• New Treatment Option for Pancreatic Cancer
• SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
• Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer
• Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
• Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
• FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
• Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy
• Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
• Valproic Acid With Chemoradiotherapy for Pancreatic Cancer
• Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer
• Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
• Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
• Gemcitabine and CT-011 for Resected Pancreatic Cancer
• A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
• Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
• Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
• Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
• Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
• Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
• Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
• Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
• Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
• Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
• Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
• Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer
• HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
• Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
• Combination With Gemcitabine in Advanced Pancreatic Cancer
• Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole
• A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
• Cancer in Patients With Gabapentin (GPRD)
• Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
• Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
• Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
• QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
• PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
• Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
• Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
• Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
• A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
• Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
• Metformin Combined With Chemotherapy for Pancreatic Cancer
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
• Gem-TABS in Unresectable Pancreatic Carcinoma
• Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
• A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer
• Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
• RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
• A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
• Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pan
• Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
• Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
• A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
• Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
• Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
• Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
• A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
• Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
• Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
• Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
• Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
• Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
• Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
• Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
• A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
• MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery
• AS703569 and Gemcitabine Combination in Advanced Malignancies
• Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
• Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency
• Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients
• Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery
• The Role of Meat-borne Carcinogens in Pancreatic Cancer
• Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
• Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
• Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
• Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
• Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
• Immunotherapy Study for Surgically Resected Pancreatic Cancer
• Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer
• Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
• A Study of Locally Advanced Pancreatic Cancer
• Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
• A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer
• Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
• Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma
• A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
• Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
• QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
• Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
• A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
• Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
• A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
• Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
• A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer
• Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
• Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surge
• Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
• Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
• Study of CellCept for Advanced Pancreatic Cancer
• Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
• Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
• High Dose Somatostatin Analogues in Neuroendocrine Tumors
• Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
• Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
• Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
• Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
• Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer
• 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
• Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer
• Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer
• Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
• Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
• ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
• Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer
• Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer
• Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
• Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
• Acceptability of Less Harmful Alternatives to Cigarettes
• Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
• Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
• Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients
• ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
• Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine
• Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
• Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
• Gemcitabine (GFF) in Patients With Pancreatic Cancer
• A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
• NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
• A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
• Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
• Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
• Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
• Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
• Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer
• Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
• Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer
• A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
• Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
• Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
• GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
• Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
• Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
• Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
• Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
• Study of Pemetrexed for Second-Line Pancreas Cancer
• A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
• Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
• Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
• 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
• A Study for Participants With Pancreatic Cancer
• Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
• Huachansu & Gemcitabine in Pancreatic Cancer
• Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
• Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
• Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
• Vorinostat Plus Radiation Therapy in Pancreatic Cancer
• Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
• Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
• A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
• Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
• Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
• Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
• Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
• A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
• Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
• Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
• Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
• MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
• Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
• Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
• Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
• Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
• Metastatic Advanced Pancreas Sorafenib
• Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
• Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
• IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
• Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
• Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
• Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
• Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
• Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
• Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
• A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
• Natural Killer Cells and Bortezomib to Treat Cancer
• A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
• Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
• APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
• Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
• Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
• Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
• Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer
• Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma
• A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
• First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
• Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
• Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
• Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
• Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
• A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
• Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
• Chemotherapy and Radiation Following Pancreatic Surgery
• Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma
• Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
• A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
• Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
• Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
• Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy
• A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
• Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
• AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
• Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
• A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
• Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
• CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
• Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
• Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
• QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
• Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
• Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
• Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
• Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
• S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
• Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
• Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
• Perioperative Therapy for Resectable Pancreatic Cancer
• S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
• Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
• Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
• Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
• Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
• Study of D-Methadone in Patients With Chronic Pain
• Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
• Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
• A Prospective Study of EUS Guided Celiac Block
• Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
• Standard and Immunostimulating Enteral Nutrition in Surgical Patients
• Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
• Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
• An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
• Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
• Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
• Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
• Nimotuzumab in Adults With Pancreatic Cancer
• A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
• The Impact of Immunostimulating Nutrition on the Outcome of Surgery
• A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
• Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
• A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
• A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
• Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
• Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
• Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
• Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
• Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
• Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
• Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
• Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
• Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
• A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
• Bupropion in Helping Adults Stop Smoking
• Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
• Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
• Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
• Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
• GEM vs GEM+TS-1 for Advanced Pancreatic Cancer
• Sirolimus in Treating Patients With Advanced Pancreatic Cancer
• Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
• Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
• Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
• AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
• Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic
• Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer
• Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
• A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
• Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
• Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
• Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
• PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca
• A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
• Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
• Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
• A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
• Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
• Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
• Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer
• Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
• A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
• Cancer of the Pancreas Screening Study (CAPS 3)
• Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
• A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
• Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery
• Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
• Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
• Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer
• Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
• Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
• Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
• Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
• Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs
• A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma
• Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
• RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
• Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
• Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
• Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
• Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer
• Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
• Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
• Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
• Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
• Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
• A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
• A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
• 131-I-TM-601 Study in Adults With Solid Tumors
• EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
• Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
• AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
• Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
• Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
• Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
• Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
• GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
• Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
• Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
• Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
• A Phase I Study of ECO-4601 in Patients With Advanced Cancer
• A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
• Preop Chemoradiation Resectable Pancreas
• Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
• Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
• Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
• A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
• Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
• Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
• Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
• ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
• Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
• Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
• Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
• Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
• Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene
• Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
• Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
• Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
• 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
• Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma
• Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
• Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
• Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
• The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer
• Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
• Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
• Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
• AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• Chemoradiation in Locally Advanced Pancreatic Cancer
• GEMOX: Oxaliplatin in Pancreatic Cancer
• Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
• Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
• Doxil Topotecan Doublet Cancer Study
• Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
• A Study of MLN8054 in Patients With Advanced Solid Tumors
• Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
• Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
• Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
• IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
• Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
• Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer
• Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
• Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
• AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
• Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
• Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
• Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
• Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
• Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
• Gemcitabine With Curcumin for Pancreatic Cancer
• Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
• Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
• Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
• Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
• A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
• Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
• Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
• Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
• Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer
• Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
• Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
• A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
• Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
• Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
• Tarceva and Capecitabine for Pancreatic Cancer
• Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
• Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
• Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
• Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
• Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
• Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
• Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
• Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
• ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
• Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
• Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
• Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
• Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
• Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
• Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Trial of Curcumin in Advanced Pancreatic Cancer
• Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
• Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
• Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
• Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
• Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
• Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
• Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
• 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
• Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
• S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
• CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
• Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
• Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
• Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
• Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
• 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
• Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
• Alanosine in Treating Patients With Cancer
• A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
• Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
• Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
• Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
• Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
• A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
• ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
• A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
• Perifosine in Treating Patients With Advanced Pancreatic Cancer
• Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
• Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
• Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
• Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
• Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
• Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
• UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
• Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
• Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
• Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
• A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer
• UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
• Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
• A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
• A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
• Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
• CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
• Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
• Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
• Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer
• Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
• Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer
• Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
• Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
• DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer
• BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery
• SU006668 in Treating Patients With Advanced Solid Tumors
• Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
• Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
• Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
• Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
• BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
• Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
• Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
• Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
• Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
• Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer
• Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
• Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
• Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
• Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
• Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
• R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
• S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer
• ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
• Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
• Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
• Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
• Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
• Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
• Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
• Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
• Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery
• DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
• Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
• Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
• Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery
• Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
• Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
• Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer
• Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
• Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
• Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
• Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
• Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
• Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
• Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
• Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
• Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
• Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach
• Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
• Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
• S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
• Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
• Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
• Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
• Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
• A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas